Table 1.
Clinicopathological characteristics of eligible studies.
| miRNA | Study | Year | Population | Sample | Histology | N | Stage | PT (Y/N/U) | Sample collection | Control group | Gender (M/F) |
Age | Method | Kits | EC | Cutoff | HR | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| miR-375 | Komatsu | 2012 | Japan | Plasma | ESCC | 50 | I–IV | 0/50/0 | Prior to surgery | normal | 44/6 | ≥65, 25; <65, 25 | qRT-PCR | TaqMan | U6 | Normal | R | OS |
| Kong | 2012 | China | Frozen | ESCC | 60 | I–IV | 0/60/0 | During resection | normal | 43/17 | ≤66, 23; >66, 37 | qRT-PCR | SYBR | SNORD48 | Normal | SC | OS/DFS | |
| Li, J | 2013 | China | FFPE | ESCC | 249 | I–IV | NG | Archive | ANT | 136/113 | ≤60, 105; >60, 144 | qRT-PCR | SYBR | 18s | NG | SC | OS | |
| Mathe | 2009 | Maryland | Frozen | AD | 73 | 0–IV | 45/27/1 | During resection | ANT | 63/10 | <62, 39; ≥62, 34 | qRT-PCR | TaqMan | U66 | Median | R | OS | |
| Canada | Frozen | AD | 27 | 0–IV | 0/27/0 | During resection | ANT | 26/1 | <62, 12; ≥62, 15 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Maryland | Frozen | ESCC | 24 | 0–IV | 14/9/1 | During resection | ANT | 12/12 | <62, 11; ≥62, 13 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Japan | Frozen | ESCC | 33 | 0–IV | 15/18/0 | During resection | ANT | 30/3 | <62, 14; ≥62, 19 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Cornell | Frozen | ESCC | 13 | 0–IV | 4/9/0 | During resection | ANT | 10/3 | <62, 3; ≥62, 10 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Nguyen | 2010 | US/Canada | Frozen | AD | 93 | 0–IV | 40/53/0 | During resection | ANT | 83/10 | 61.7, 93 | qRT-PCR | TaqMan | U66 | Median | R | OS | |
| Wu | 2014 | China | Serum | ESCC | 194 | I–IV | 0/194/0 | Prior to surgery | normal | 115/79 | 61.4, 194 | qRT-PCR | TaqMan | U6 | Mean | R | OS | |
| miR-21 | Hamano | 2011 | Japan | FFPE | ESCC | 98 | I–IV | 98/0/0 | Archive | ANT | 84/14 | High: 63.2 ± 8.5; Low: 60.0 ± 8.6 |
qRT-PCR | TaqMan | U48 | Median | SC | OS |
| Hu | 2011 | USA | FFPE | AD | 158 | 0–IV | 0/158/0 | Archive | ANT | 127/31 | 28–82, median 64 | ISH | NG | NG | NG | R | OS/DFS | |
| Komatsu | 2013 | Japan | Plasma | ESCC | 50 | I–IV | 0/50/0 | Prior to surgery | normal | 44/6 | ≥65, 25; <65, 25 | qRT-PCR | TaqMan | U6 | Normal | R | OS | |
| Li, P | 2013 | China | Frozen | ESCC | 76 | I–IV | NG | During resection | Normal | 61/15 | ≥65, 29; <65, 47 | qRT-PCR | SYBR | U6 | 5-fold | SC | DFS | |
| Mathe | 2009 | Maryland | Frozen | AD | 73 | 0–IV | 45/27/1 | During resection | ANT | 63/10 | <62, 39; ≥62, 34 | qRT-PCR | TaqMan | U66 | Median | R | OS | |
| Canada | Frozen | AD | 27 | 0–IV | 0/27/0 | During resection | ANT | 26/1 | <62, 12; ≥62, 15 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Maryland | Frozen | ESCC | 24 | 0–IV | 14/9/1 | During resection | ANT | 12/12 | <62, 11; ≥62, 13 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Japan | Frozen | ESCC | 33 | 0–IV | 15/18/0 | During resection | ANT | 30/3 | <62, 14; ≥62, 19 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Cornell | Frozen | ESCC | 13 | 0–IV | 4/9/0 | During resection | ANT | 10/3 | <62, 3; ≥62, 10 | qRT-PCR | TaqMan | U66 | Median | R | OS | |||
| Tanaka | 2013 | Japan | Serum | ESCC | 64 | I–IV | 0/64/0 | Prior to surgery | Normal | 49/15 | ≥65, 42; <65, 22 | qRT-PCR | TaqMan | miR-39 | Median | SC | PFS | |
| Zhao | 2013 | China | Frozen | ESCC | 178 | I–III | 0/178/0 | During resection | ANT | 108/70 | 34–78, mean 62.2 | qRT-PCR | TaqMan | U66 | Median | SC | OS | |
| miR-145 | Feber | 2011 | US | Frozen | AD | 45 | I–IV | 0/45/0 | During resection | ANT | 38/7 | NG | qRT-PCR | NG | U6 | Median | SC | OS |
| Hamano | 2011 | Japan | FFPE | ESCC | 98 | I–IV | 98/0/0 | Archive | ANT | 84/14 | High: 63.2 ± 8.5; Low: 60.0 ± 8.6 |
qRT-PCR | TaqMan | U48 | Median | SC | OS | |
| Ko | 2012 | Canada | FFPE | EC | 25 | III | 0/25/0 | Archive | PS | NG | NG | Microarray | BeadChip | NG | Median | SC | DFS | |
| Tanaka | 2013 | Japan | Serum | ESCC | 64 | I–IV | 0/64/0 | Prior to surgery | Normal | 49/15 | ≥65, 42; <65, 22 | qRT-PCR | TaqMan | miR-39 | Median | SC | PFS |
FFPE, formalin-fixed paraffin-embedded; PT (Y/N/U), preoperative treatment (yes, no, unknown); PS, posttreatment specimens; ISH, in situ hybridization; ANT, adjacent noncancerous tissue; R, reported; SC, survival curve; NG, not given; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival.